Publication of Phase 2 Clinical Analyses of Gut Microbiome Health
(WorldNews Environment)

Summit Therapeutics plc (`Summit` or the `Company`) Summit Announces Publication of Phase 2 Clinical Analyses of Gut Microbiome Health Oxford, UK, and Cambridge, MA, US, July 13, 2020 - Summit Therapeutics plc (NASDAQ: SMMT) today announces the publication of data from the Phase 2 clinical trial of the company`s precision antibiotic, ridinilazole, in development for the treatment of C. difficile infection (`CDI`) in the American Journal of Physiology - Gastrointestinal and Liver Physiology. The data published in collaboration with researchers at Tufts University and Tufts Medical Center demonstrated that ridinilazole`s microbiome preservation resulted in a gut environment expected to inhibit...